Thyroid Care Through a Physiology-First, Integrative Lens

Abstract

In this educational post, I walk you through a physiology-first approach to thyroid care that I have refined over the years as both a clinician and a thyroid patient. I explain why many individuals remain symptomatic on levothyroxine despite a “normal” thyroid-stimulating hormone, how deiodinase enzymes, tissue-specific T3 signaling, and reverse T3 shape real outcomes, and why a TSH-only strategy often misses what truly matters: intracellular T3. I translate leading research into a practical clinical framework that includes comprehensive testing (free T3, free T4, reverse T3), the metabolic and inflammatory context, the cardiometabolic implications of low T3, and individualized therapy that may include combination T4/T3 or desiccated thyroid extract. I also show how integrative chiropractic care supports autonomic balance, movement, mitochondrial health, and the neuroimmune axis, thereby improving thyroid signaling. You will discover an evidence-based, step-by-step strategy that restores tissue euthyroidism—not just normal lab numbers—supported by citations and the latest methods.

Why Physiology Must Lead Modern Thyroid Care

When we overlook tissue-level thyroid physiology, patients suffer. In my clinical practice, I repeatedly meet people who have “normal” TSH yet remain fatigued, cold, constipated, with hair thinning and weight gain. When we honor how the body regulates local T3 inside tissues—not just hormones in the bloodstream—outcomes improve.

• Key principles I teach and use in practice:
  • Thyroid hormone action is local: tissues fine-tune T4-to-T3 activation through deiodinase enzymes (Bianco & da Conceição, 2018).
  • TSH is a pituitary snapshot, not a universal proxy for all tissues (Biondi & Wartofsky, 2014).
  • Reverse T3 (rT3) functions as a metabolic brake during stress and illness (Fliers, Kalsbeek, & Boelen, 2015).
  • T4-only therapy assumes perfect conversion to T3, which fails in a sizable subset (Jonklaas et al., 2014).

My goal is to restore tissue euthyroidism—the state in which muscles, liver, heart, brain, and gut are receiving adequate T3—rather than chasing a single lab value.

Thyroid Physiology 101: Why T3 Drives Cellular Metabolism

To make care work in the real world, we must anchor in physiology:

• T4 (thyroxine) is a prohormone with low receptor affinity; it is best understood as a circulating reservoir.
• T3 (triiodothyronine) binds nuclear thyroid receptors with far greater affinity and drives gene programs that regulate mitochondrial biogenesis, oxidative metabolism, thermogenesis, GI motility, lipid and glucose handling, neuromuscular tone, and cognition (Mullur, Liu, & Brent, 2014).
• Deiodinases (DIO1, DIO2, DIO3) are selenium-dependent enzymes that regulate local thyroid action (Bianco & da Conceição, 2018):
  • DIO1 (liver, kidney, thyroid): creates circulating T3 and clears rT3.
  • DIO2 (brain, pituitary, brown adipose tissue, skeletal muscle): generates intracellular T3 where it is used.
  • DIO3 (brain, placenta, stressed tissues): inactivates T4 and T3, generating rT3 and T2 to protect cells in stress or illness.

When stress, inflammation, insulin resistance, or nutrient deficits depress DIO1/DIO2 and upregulate DIO3, the result is low free T3 and elevated rT3—a pattern I frequently see in T4-treated patients who remain symptomatic (Fliers, Kalsbeek, & Boelen, 2015; van der Spek, Fliers, & Boelen, 2017).

Why this matters: once-daily T4 boluses rely on deiodinases to locally convert T4 to T3. If that system is impaired, blood T4 can be “normal” while cells are T3-starved.

The TSH Problem: A Screening Test Misused for Treatment

The original purpose of TSH was screening for primary hypothyroidism, not managing already treated patients. The pituitary is uniquely buffered by robust DIO2 activity, which maintains local T3 levels even when peripheral tissues are T3-deficient (Biondi & Wartofsky, 2014). In practice:

• TSH can be normal or low while muscles, liver, and heart remain under-stimulated by T3.
• Many T4-treated patients with normal TSH report reduced quality of life and persistent symptoms (Jonklaas et al., 2014).
• Suppressed TSH on therapy is not, by itself, proof of overtreatment; context matters, including free T3, free T4, pulse, symptoms, and risks (Biondi, 2012; Flynn et al., 2010).

In my clinic, I do run TSH as a risk screen and to understand axis context, but I do not rely on it to guide therapy in symptomatic, treated patients. I prioritize free T3, free T4, rT3, and clinical endpoints.

Reverse T3: The Metabolic Brake That Explains “Normal Labs, Hypothyroid Life”

When the organism perceives a threat—acute illness, systemic inflammation, sleep loss, caloric restriction, or high-dose T4—DIO3 increases, shunting T4 toward rT3. Elevated rT3 competitively limits T3 signaling, effectively braking metabolism to conserve resources (Fliers, Kalsbeek, & Boelen, 2015).

• Clinical pattern I see often:
  • High-normal free T4, low or low-normal free T3, elevated rT3, and “normal” TSH.
  • Symptoms: fatigue, cold intolerance, bradycardia/low resting pulse, constipation, hair thinning, slow reflexes.

Measuring rT3 helps distinguish “not enough T3 produced” from “T3 being blocked” and guides whether to improve conversion terrain or add T3 to bypass the bottleneck.

Why T4-Only Therapy Often Falls Short

The human thyroid releases a steady, blended signal of T1, T2, T3, T4, and calcitonin across the day. Once-daily T4 monotherapy assumes the body will convert T4 to T3 in the right amounts at the right times. For many patients, that assumption fails due to:

• Deiodinase polymorphisms (for example, Thr92Ala in DIO2) and tissue differences in DIO expression (Mullur, Liu, & Brent, 2014).
• Stress and inflammation (IL-6, TNF-?) that downregulate DIO1/DIO2 and upregulate DIO3 (Fliers, Kalsbeek, & Boelen, 2015).
• Insulin resistance, NAFLD, and gut-liver dysfunction that reduce conversion and alter binding proteins (van der Spek, Fliers, & Boelen, 2017).
• In clinical trials and pragmatic studies, adding T3 to T4 improves symptoms in subsets (Appelhof et al., 2005; Hoang et al., 2013).

This is why a patient on high-dose T4 with fatigue, cold intolerance, and hair loss is “under-treated at the tissue level” until proven otherwise.

Cardiometabolic Implications: Low T3 and the Heart

The heart is exquisitely sensitive to T3. Cardiology data show that low T3 in heart failure, acute myocardial infarction, and other cardiac contexts is associated with worse outcomes, prolonged QTc, and higher mortality (Iervasi et al., 2003; Pingitore et al., 2012; Wang et al., 2019).

Mechanisms include T3’s regulation of:

• SERCA2a and intracellular calcium handling,
• Mitochondrial ATP generation,
• Nitric oxide bioavailability and vascular compliance,
• Ion-channel expression affecting repolarization and QT intervals (Rosenbaum et al., 2022).

In my clinic, when we correct low T3 patterns thoughtfully—often by addressing conversion bottlenecks and, when appropriate, adding liothyronine—patients frequently note improved exercise tolerance and heart rate variability, changes that mirror the physiology.

A Physiology-First Diagnostic Panel: Seeing the Whole Terrain

I start with a comprehensive view to locate the true bottlenecks:

• Thyroid axis:
  • TSH (screen and context)
  • Free T4, Free T3
  • Reverse T3 (rT3)
  • Thyroid antibodies (TPOAb, TgAb) when autoimmunity is suspected
  • SHBG as a surrogate for hepatic thyroid effects and androgen/estrogen milieu
• Metabolic and inflammatory context:
  • CBC, CMP, fasting lipids, fasting insulin/HOMA-IR, HbA1c
  • hs-CRP, ESR, ferritin, full iron studies
  • Selenium, zinc, vitamin D, B12/folate, magnesium
  • Morning cortisol and, when indicated, diurnal assessments
  • ALT/AST/GGT for NAFLD risk
  • Celiac screen (tTG-IgA) if malabsorption is suspected
• Physiologic markers and patient-reported outcomes:
  • Resting pulse, blood pressure, and basal temperature trends
  • GI transit, stool patterns, hair/skin exam, tendon reflexes
  • Validated fatigue scales, cold intolerance scores, GI symptoms, and quality-of-life indices

Why this panel: it distinguishes production failure from conversion failure, identifies rT3 excess, and uncovers nutrient and inflammatory barriers that undermine deiodinases (Jonklaas et al., 2014; Biondi & Wartofsky, 2014).

Treatment Strategy: Restoring Tissue Euthyroidism

My north star is simple: safely restore intracellular T3 signaling. The path is individualized and grounded in physiology.

Step 1: Optimize the Terrain Before Tweaking the Dose

• Reduce inflammatory load:
  • Treat periodontal disease, improve gut health, eliminate ultra-processed foods, and moderate alcohol intake.
• Stabilize sleep and circadian rhythm:
  • Aim for 7.5–9 hours; treat sleep apnea; anchor light exposure.
• Ensure caloric and protein adequacy:
  • Avoid chronic underfeeding; target protein to support mitochondrial and thyroid function.
• Train smart:
  • Blend resistance training with aerobic base work; avoid exhaustive chronic cardio that elevates cortisol.
• Correct micronutrient deficits:
  • Selenium 100–200 mcg/day (as indicated) for deiodinase support and antibody modulation (Ventura, Melo, & Carrilho, 2017).
  • Zinc for receptor function and transporters.
  • Iron sufficiency for thyroid peroxidase and oxygen delivery (Zimmermann & Köhrle, 2002).
  • Vitamin D, magnesium, and B vitamins for immune and energy metabolism.

Rationale: lowering cytokines and cortisol allows DIO1/DIO2 to recover, reduces DIO3, and improves conversion.

Step 2: Personalize Thyroid Pharmacotherapy

• When T4-only is acceptable:
  • Patients with robust conversion, normal rT3, and symptom resolution.
• When to add T3:
  • Low free T3 and elevated rT3 on adequate T4,
  • Persistent symptoms despite normal TSH/free T4,
  • Suspected DIO2 polymorphism or central-peripheral mismatch.
• How I add T3:
  • Liothyronine in small, divided doses (2.5–5 mcg once or twice daily), paired with a modest T4 reduction to avoid thyrotoxicosis.
  • Target T4:T3 ratios approximating physiologic output (about 13:1 to 16:1 by weight), and titrate to clinical response (Wiersinga, 2014; Appelhof et al., 2005).
• Desiccated thyroid extract (DTE):
  • Fixed T4:T3 ratio with trace T1/T2; helpful for some who do not thrive on T4 alone (Hoang et al., 2013).
  • Monitor free T3 carefully; avoid supraphysiologic peaks through dosing and lab timing.
• Monitoring:
  • Reassess symptoms, vitals, and labs in 6–8 weeks; do not over-rely on TSH in T3-containing regimens.

Rationale: adding T3 bypasses conversion bottlenecks and directly restores receptor activation where it counts.

Timing Matters: Standardizing Labs for T3-Containing Therapy

One of the most underappreciated errors in practice is variable lab timing. For any T3-containing therapy (DTE or liothyronine), I standardize lab draws to 5–6 hours after the morning dose. Drawing too early falsely elevates free T3; drawing too late makes it appear low. By fixing the timing, we can compare true changes over time and titrate safely.

Integrative Chiropractic Care: Amplifying Thyroid Therapy Through the Neuroimmune Axis

Integrative chiropractic care does not “cure” hypothyroidism; it optimizes the terrain so endocrine therapies work better. In my practice, I see consistent gains when manual and movement-based care is combined with medical management:

• Autonomic regulation:
  • Gentle spinal and rib mobilization, cervical-thoracic adjustments when indicated, and breathing-driven vagal maneuvers shift sympathetic overdrive toward parasympathetic tone. Improved vagal activity reduces IL-6/TNF-? signaling and DIO3 upregulation, supporting T3 generation (Tracey, 2002).
• Movement prescription and mitochondrial support:
  • Progressive resistance training and zone 2 aerobic base increase AMPK-PGC-1? signaling and mitochondrial density, enhancing responsiveness to T3.
• Myofascial and lymphatic optimization:
  • Instrument-assisted soft tissue work and lymphatic techniques improve microcirculation and reduce nociceptive drive, which in turn lowers cortisol and catecholamines that otherwise push rT3.
• Respiration mechanics and posture:
  • Ribcage and diaphragm-focused work improves CO2 tolerance, sleep depth, and autonomic flexibility, all of which favor deiodinase balance.

Clinical observations from my case notes consistently show that patients receiving integrative care stabilize faster on T3-containing regimens, report fewer afternoon crashes, and maintain steadier mood and HRV across 6–12 weeks of therapy.

• Clinical observations and protocols: https://chiropracticscientist.com/
• Professional updates: https://www.linkedin.com/in/dralexjimenez/

Common Clinical Patterns And How I Respond

• Pattern 1 Normal TSH, normal free T4, low free T3, high rT3
  • What I see: fatigue, cold intolerance, low resting pulse, constipation, and hair thinning.
  • My plan: reduce T4 modestly and add low-dose T3 in divided doses; implement anti-inflammatory nutrition, sleep repair, and selenium and zinc repletion; reassess in 6–8 weeks, aiming for a mid-to-upper-range free T3 (with standardized timing) and improved vitals and symptoms.
• Pattern 2 Suppressed TSH on therapy, asymptomatic, normal free T3/T4, normal pulse
  • Concern: “Am I over-treated?”
  • My approach: explain that TSH suppression alone does not equate to overtreatment; confirm euthyroid status with free T3/free T4 and clinical assessment; continue current dosing if stable; monitor bone density and rhythm risk per guidelines.
• Pattern 3 Hashimoto’s with fluctuating symptoms
  • My plan: stabilize iodine intake, ensure selenium sufficiency, address gut permeability and dysbiosis; adjust dosing conservatively; avoid large T4 swings that can spur rT3 spikes.

Bones, Heart Rhythm, Hair: Sorting Risk From Reality

• Hair loss:
  • Hypothyroidism commonly causes telogen effluvium. Restoring tissue T3 improves hair cycling; a suppressed TSH with physiologic free T3 and normal pulse is unlikely to cause hair loss. I also assess iron, zinc, vitamin D, and androgens.
• Bone health:
  • Overt hyperthyroidism increases fracture risk, but TSH suppression alone without elevated free T3/free T4 does not always equate to thyrotoxicosis. I monitor bone health in at-risk patients and individualize therapy (Flynn et al., 2010; Biondi, 2012).
• Atrial fibrillation:
  • Arrhythmia risk tracks with excess free T3/free T4 and clinical thyrotoxicosis rather than TSH alone. I monitor pulse and ECG in at-risk patients and keep free T3 within physiologic range.

The antidote to fear is contextual measurement and careful titration.

Practical Protocol: Step-by-Step Roadmap For Care

• Baseline assessment:
  • Detailed symptom inventory (energy, temperature, bowels, hair/skin, mood, cognition, menstrual/androgen status), vitals (pulse, BP, temperature trends), and autonomic markers (HRV when available).
  • Labs: TSH, free T4, free T3, rT3, thyroid antibodies; iron panel with ferritin; selenium, zinc, vitamin D; hs-CRP; fasting insulin/glucose; lipid panel.
• First 4–6 weeks:
  • Emphasize sleep consolidation, circadian timing, anti-inflammatory nutrition; correct deficiencies; begin low-intensity aerobic base and gentle mobility; implement integrative manual care to reduce nociception and sympathetic tone.
• Weeks 6–12:
  • Reassess symptoms and labs (with standardized timing for T3); if free T3 remains low or rT3 high, collaborate to adjust therapy (introduce divided T3 dosing or DTE and reduce T4 as indicated).
  • Progress resistance training, expand breathwork, and monitor HRV.
• Ongoing:
  • Trend labs and symptoms every 6–12 weeks until stable, then every 6–12 months; monitor bone and cardiac parameters as risk dictates; sustain lifestyle strategies that protect deiodinase function and mitochondrial efficiency.

Each step targets a specific physiologic lever—reducing D3-promoting stress and inflammation, supporting D1/D2 with nutrients and movement, optimizing absorption and diurnal patterns, and delivering the right T3 signal to the right tissues at the right time.

Safety, Individualization, and Outcome Tracking

• Safety first:
  • Avoid abrupt changes that can provoke palpitations or overtreatment. For patients with cardiovascular disease or osteoporosis risk, I coordinate care and titrate conservatively.
• Individualization:
  • Age, sex hormones, genetics (including DIO2 polymorphisms), insulin resistance, hepatic function, and autoimmunity shape response. I tailor therapy to these realities.
• Outcome tracking:
  • I track beyond labs: exercise tolerance, HRV, sleep efficiency, cognitive function, stool regularity, hair, and skin changes. Thyroid health is lived in daily function, not just seen on paper.

Integrative Chiropractic Care In Context: Why It Fits

My integrative chiropractic lens helps patients lean into physiology. By reducing nociceptive load and sympathetic arousal, we often see a decline in cortisol and catecholamines—freeing DIO1/DIO2 and dampening DIO3 activity, which helps normalize rT3 and raise free T3. Better ribcage mechanics and diaphragmatic breathing deepen sleep and improve HRV, stabilizing the hypothalamic-pituitary-thyroid axis. Movement prescriptions that build mitochondrial capacity make tissues more receptive to T3. When these strategies ride alongside carefully titrated hormone therapy, patients usually stabilize more quickly and durably.

For a window into my case-informed strategies and ongoing clinical reflections, visit my pages:

• https://chiropracticscientist.com/
• https://www.linkedin.com/in/dralexjimenez/

Putting It All Together: A Patient-Centered, Evidence-Aligned Path

• Respect deiodinase biology and tissue-level T3 signaling.
• Use free T3, free T4, and rT3 with symptoms and vitals—not TSH alone—to track treated patients.
• Correct nutrient and inflammatory barriers that suppress D1/D2 and upregulate D3.
• Consider T3 addition or DTE when conversion fails—using physiologic ratios and divided dosing with standardized lab timing.
• Integrate chiropractic and rehabilitative methods to optimize autonomic balance, microcirculation, and mitochondrial readiness.
• Prioritize safety with bone and cardiac monitoring and accurate, standardized lab interpretation.

When we align therapy with how the body actually works—moment to moment—patients move from “in range” to truly well. That is the promise of physiology-first thyroid care.

References

• Appelhof, B. C., Fliers, E., Wekking, E. M., et al. (2005). Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism. Journal of Clinical Endocrinology & Metabolism, 90(5), 2666–2674.
• Bianco, A. C., & da Conceição, R. R. (2018). The deiodinase trio and thyroid hormone signaling. Molecular and Cellular Endocrinology, 458, 6–12.
• Biondi, B. (2012). Natural history, diagnosis and management of subclinical thyroid dysfunction. Endocrine Reviews, 33(1), 78–131.
• Biondi, B., & Wartofsky, L. (2014). Treatment with thyroid hormone. Endocrine Reviews, 35(3), 433–512.
• Fliers, E., Kalsbeek, A., & Boelen, A. (2015). Mechanisms in Endocrinology: Beyond the fixed setpoint of the hypothalamus–pituitary–thyroid axis. European Journal of Endocrinology, 172(4), R197–R208.
• Flynn, R. W., Bonellie, S. R., Jung, R. T., et al. (2010). Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology & Metabolism, 95(1), 186–193.
• Hoang, T. D., Olsen, C. H., Mai, V. Q., et al. (2013). Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism. Journal of Clinical Endocrinology & Metabolism, 98(5), 1982–1990.
• Iervasi, G., Molinaro, S., Landi, P., et al. (2003). Association between low T3 syndrome and mortality in cardiac patients. Circulation, 107(5), 708–713.
• Jonklaas, J., Bianco, A. C., Bauer, A. J., et al. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid, 24(12), 1670–1751.
• Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014). Thyroid hormone regulation of metabolism. Physiological Reviews, 94(2), 355–382.
• Pingitore, A., Galli, E., Barison, A., et al. (2012). Acute effects of triiodothyronine replacement therapy in patients with chronic heart failure and low-T3 syndrome. Journal of Clinical Endocrinology & Metabolism, 97(7), 2500–2508.
• Rosenbaum, A. N., Edwards, B. S., & Scott, C. G. (2022). Thyroid hormones and the heart: A contemporary review. Current Heart Failure Reports, 19(1), 1–12.
• van der Spek, A. H., Fliers, E., & Boelen, A. (2017). Thyroid hormone transporters and deiodinases in the control of thyroid hormone homeostasis. Journal of Clinical Endocrinology & Metabolism, 102(10), 3864–3875.
• Ventura, M., Melo, M., & Carrilho, F. (2017). Selenium and thyroid disease: From pathophysiology to treatment. International Journal of Endocrinology, 2017, 1297658.
• Wang, X., Zhu, H., Wang, J., et al. (2019). Low triiodothyronine syndrome and prognosis in patients with cardiovascular diseases: A meta-analysis. Clinical Cardiology, 42(7), 732–739.
• Wiersinga, W. M. (2014). Paradigm shifts in thyroid hormone replacement therapies. Nature Reviews Endocrinology, 10(3), 164–174.
• Zimmermann, M. B., & Köhrle, J. (2002). The impact of iron and selenium deficiencies on iodine and thyroid metabolism. Endocrine Reviews, 23(4), 605–635.
• Tracey, K. J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859.